Literatur
- 1
Antonelli G, Turriziani O, Verri A. et al .
Long-term exposure to Zidovudine affects
in vitro and in vivo the efficiency of phosphorylation of thymidine
kinase.
AIDS Res Hum Retrov.
1996;
12
223-228
- 2
Back D J.
Pharmacological
issues relating to viral resistance.
Infection.
1999;
27
S42-44
- 3
Baxter J D, Mayers D L, Wentworth D N. et al .
A randomized study of antiretroviral management
based on plasma genotypic antiretroviral resistance testing in patients
failing therapy. CPCRA 046 Study Team for the Terry Beirn Community
Programs for Clinical Research on AIDS.
AIDS.
2000;
14
83-93
- 4
Berger A, Preiser W, Doerr H W.
The role of
viral load determination for the management of human immunodeficiency
virus, hepatitis B virus and hepatitis C virus infection.
J
Clin Virol.
2001;
20
23-30
- 5
Bradley G, Juranka P F, Ling V.
Mechanisms
of multidrug resistance.
Biochem Biophys Acta.
1988;
948
87-128
- 6
Brockmeyer N H, Salzberger B, Doerr H W, Marcus U, Brodt H R.
Antiretrovirale
Therapie der HIV-Infektion.
Deutsches Ärzteblatt.
2001;
4
A175-A81
- 7
Cinatl J Jr, Cinatl J, Weber B. et al .
Decreased anti-human immunodeficiency virus
type-1 activities of 2’,3’-dideoxynucleoside analogs
in Molt-4 cell sublines resistant to 2’,3’-dideoxynucleoside analogs.
Acta
Virol.
1993;
37
360-368
- 8
Cinatl J Jr, Gröschel B, Zehner R. et al .
HIV resistance to AZT in MOLT-4/8
cells is associated with the lack of AZT phosphorylation and is
bypassed by AZT-monophosphate SATE-prodrugs.
Antivir Chem
Chemoth.
1997;
8
343-352
- 9
Clevenbergh P, Durant J, Halfon P. et al .
Persisting long-term benefit of antiretroviral
genotypic guided treatment for HIV-infected patients failing HAART.
Antiviral
Ther (Abstract 60).
1999;
4
42
- 10
Cohen C, Dessler H, Hunt S. et al .
Phenotypic
resistance testing significantly impoves response to therapy: final
analysis of a randomized trial (VIRA3001).
Antivir Ther.
2000;
5
67
- 11
Draenert R, Goebel F D.
Empfehlungen
und Perspektiven der antiretroviralen Therapie.
Dtsch
Med Wochenschr.
2001;
126
539-543
- 12
Durant J, Clevenbergh P, Halfon P. et al .
Drug-resistance genotyping in HIV-1 therapy:
the VIRADAPT randomised controlled trial.
Lancet.
1999;
353
2195-2199
- 13
Eberlein B, Baur A, Neundorfer M, Jahn G.
Expression of human immunodeficiency
virus (HIV) in naturally infected peripheral blood mononuclear cells:
comparison of a standard co-culture technique with a newly developed
microculture method.
Virus Res.
1991;
19
153-161
- 14
EuroGuidelines Group for
HIV resistance .
Clinical and laboratory guidelines
for the use of HIV-1 drug resistance testing as part of treatment
management: recommendations for the European setting.
AIDS.
2001;
15
309-320
- 15
Font E, Rosario O, Santana J, Garcia H, Sommadossi J P, Rodriguez J F.
Determination
of zidovudine triphosphate intracellular concentrations in peripheral
blood mononuclear cells from human immunodeficiency virus-infected
individuals by tandem mass spectrometry.
Antimicrob Agents
Chemother.
1999;
43
2964-2968
- 16
Deutsche AIDS-Gesellschaft
(DAIG). Osterreichische AIDS-Gesellschaft (OAG) .
German-Austrian
guidelines for antiretroviral therapy in HIV infection. June 1999.
Eur
J Med Res.
2000;
5
129-138
- 17
Gröschel B, Cinatl J, Cinatl J Jr.
Viral
and cellular factors for resistance against antiretroviral agents.
Intervirology.
1997;
40
400-407
- 18
Gröschel B, Cinatl J, Miller V, Doerr H W, Cinatl J Jr.
Activity
of thymidine kinase 1 in PBMCs of HIV-1 infected patients: novel
therapy marker.
Infection.
2000;
28
209-213
- 19
Gröschel B, Himmel N, Cinatl J. et al .
ddC- and 3TC-bis(SATE) monophosphate prodrugs
overcome cellular resistance mechanisms to HIV-1 associated with
cytidine kinase deficiency.
Nucleos Nucleot.
1999a;
18
9219-9226
- 20
Gröschel B, Meier C, Zehner R, Cinatl J, Doerr H W, Cinatl J Jr.
Effects of
cycloSal-d4TMP derivatives in H9 cells with induced AZT resistance
phenotype.
Nucleos Nucleot.
1999b;
18
933-936
- 21
Hammer S M, Squires K E, Hughes M D. et al .
A controlled trial of two nucleoside analogues
plus indinavir in persons with human immunodeficiency virus infection
and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical
Trials Group 320 Study Team.
N Engl J Med.
1997;
337
725-733
- 22
Hertogs K, de Bethune M P, Miller V. et al .
A rapid method for simultaneous detection
of phenotypic resistance to inhibitors of protease and reverse transcriptase
in recombinant human immunodeficiency virus type 1 isolates from
patients treated with antiretroviral drugs.
Antimicrob
Agents Chemother.
1998;
42
269-276
- 23
Hertogs K, Bloor S, De Vroey V. et al .
A novel human immunodeficiency virus type
1 reverse transcriptase mutational pattern confers phenotypic lamivudine
resistance in the absence of mutation 184V.
Antimicrob
Agents Chemother.
2000;
44
568-573
- 24
Jacobsson B, Britton S, He Q, Karlsson A, Eriksson S.
Decreased thymidine
kinase levels in peripheral blood cells from HIV-seropositive individuals:
implications for zidovudine metabolism.
AIDS Res Hum
Retroviruses.
1995;
11
805-811
- 25
Japour A J, Mayers D L, Johnson V A. et al .
Standardized peripheral blood mononuclear
cell culture assay for determination of drug susceptibilities of
clinical human immunodeficiency virus type 1 isolates. The RV-43
Study Group, the AIDS Clinical Trials Group Virology Committee Resistance
Working Group.
Antimicrob Agents Chemother.
1993;
37
1095-1101
- 26
Kellam P, Larder B A.
Recombinant
virus-assay: a rapid, phenotypic assay for assessment of drug susceptibility
of human immunodeficiency virus type 1 isolates.
Antimicrob
Agents Chemother.
1994;
38
23-30
- 27
Kim R B, Fromm M F, Wandel C. et al .
The drug transporter P-glycoprotein limits
oral absorption and brain entry of HIV-1 protease inhibitors.
J
Clin Invest.
1998;
101
289-294
- 28
Larder B A, Darby G, Richmann D D.
HIV
with reduced sensitivity to zidovudine (AZT) isolated during prologned
therapy.
Science.
1989;
243
1731-1734
- 29
Martinez-Picado J, DePasquale M P, Kartsonis N. et al .
Antiretroviral resistance during successful
therapy of HIV type 1 infection.
Proc Natl Acad Sci USA.
2000;
97
10 948-10 953
- 30
Mellors J W, Rinaldo C R, Gupta P, White R M, Todd J A, Kingsley L A.
Prognosis
in HIV-1 infection predicted by the quantity of virus in plasma.
Science.
1996;
272
1167-1170
- 31
Miller V, de Bethune M P, Kober A. et al .
Patterns of resistance and cross-resistance
to human immunodeficiency virus type 1 reverse transcriptase inhibitors
in patients treated with the nonnucleoside reverse transcriptase
inhibitor loviride.
Antimicrob Agents Chemother.
1998;
42
3123-3129
- 32
Miller V, Sabin C A, Phillips A N. et al .
The impact of protease inhibitor-containing
highly active antiretroviral therapy on progression of HIV disease
and its relationship to CD4 and viral load.
AIDS.
2000;
14
2129-2136
- 33
Palella F J, Delaney K M, Moorman A C. et al .
Declining morbidity and mortality among
patients with advanced human immunodeficiency virus infection.
N
Engl J Med.
1998;
338
853-860
- 34
Petropoulos C J, Parkin N T, Limoli K L. et al .
A novel phenotypic drug susceptibility
assay for human immunodeficiency virus type 1.
Antimicrob
Agents Chemother.
2000;
44
920-928
- 35 Robert Koch Institut .Berichte
des AIDS-Zentrums im Robert Koch Institut über aktuelle
epidemiologische Daten in Deutschland (Stand 31.12.2000). Epidemiologisches
Bulletin/Sonderausgabe A 2001;27Feb: 1-16
- 36
Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger U M, Schwab M.
Frequency
of C34/35T polymorphism of MDR1 gene in African people.
Lancet.
2001;
358
383-384
- 37
Schuetz J D, Connelly M C, Sun D. et al .
A MRP4: A previously unidentified factor
in resistance to nucleoside-based antiviral drugs.
Nat
Med.
1999;
5
1048-1051
- 38
Spielhofen A, Gröschel B, Cinatl J Jr, Doerr H W.
Genotypic and
phenotypic resistance testing PCR negative HIV-1 patients on HAART.
J
Clin Virol.
2000;
18
48
- 39
Spina C A, Prince H E, Richman D D.
Preferential
replication of HIV-1 in the CD45RO memory cell subset of primary
CD4 lymphocytes in vitro.
J Clin Invest.
1997;
99
1774-1785
- 40
Stuyver L, Wyseur A, Rombout A. et al .
Line probe assay for rapid detection of
drug-selected mutations in the human immunodeficiency virus type
1 reverse transcriptase gene.
Antimicrob Agents Chemother.
1997;
41
284-291
- 41
Tremblay C L, Giguel F, Merrill D P. et al .
Marked differences in quantity of infectious
human immunodeficiency virus type 1 detected in persons with controlled
plasma viremia by a simple enhanced culture method.
J
Clin Microbiol.
2000;
38
4246-4248
- 42
Vahey M, Nau M E, Barrick S. et al .
Performance
of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral
drug resistance genotyping of human immunodeficiency virus type
1 clades and viral isolates with length polymorphisms.
J
Clin Microbiol.
1999;
37
2533-2537
- 43
Walter H, Schmidt B, Korn K, Vandamme A M, Harrer T, Uberla K.
Rapid,
phenotypic HIV-1 drug sensitivity assay for protease and reverse
transcriptase inhibitors.
J Clin Virol.
1999;
13
71-80
- 44
Wijnholds J, Mol C A, van Deemter L. et al .
Multidrug-resistance protein 5 is a multispecific
organic anion transporter able to transport nucleotide analogs.
Proc
Natl Acad Sci USA.
2000;
97
7476-7481
- 45
Wilson J W, Bean P, Robins T, Graziano F, Persing D H.
Comparative evaluation
of three human immunodeficiency virus genotyping systems: the HIV-GenotypR
method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe
assay.
J Clin Microbiol.
2000;
38
3022-3028
- 46
Wong J K, Hezareh M, Gunthard H F. et al .
Recovery of replication-competent HIV despite
prolonged suppression of plasma viremia.
Science.
1997;
278
1291-1295
- 47
Zhang Y M, Imamichi H, Imamichi T. et al .
Drug resistance during indinavir therapy
is caused by mutations in the protease gene and in its gag substrate
cleavage sites.
J Virol.
1997;
71
6662-6670
Korrespondenz
Dr. Bettina Gröschel
Institut für Medizinische Virologie, Johann
Wolfgang Goethe-Universität Frankfurt/Main
Paul-Ehrlich Straße 40
60596 Frankfurt/Main
Phone: 069/6301-7747
Fax: 069/6301-4302
Email: Groeschel@em.uni-frankfurt.de
